Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-adapted bortezomib add-on therapy after insufficient Rd response in transplant-ineligible newly diagnosed multiple myeloma
jRCTs071180011Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lenalidomide, dexamethasone and bortezomib in multiple myeloma (MM), sponsored by Bristol Myers Squibb. Primary endpoint: Complete response rate up to 18 cycles. Started Jun 2017; status: active, not recruiting.
02
Drugs
lenalidomidedexamethasonebortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCTs071180011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180011.